Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2350)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (23)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4746)
  2. Department of Medicine (4744)
  3. Center for Pancreatic Cancer Research (2313)
  4. Surgery (1066)
  5. Survivorship Research (1014)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (221)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (148)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (321)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4746)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions
    Meeting Abstract

    Makawita, S.; Kelley, R. K.; Roychowdhury, S.; Weiss, K. H.; Abou-Alfa, G. K.; Macarulla, T.; Sadeghi, S.; Waldschmidt, D.; Zhu, A. X.; Goyal, L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Abou-Alfa, G. K.; Shi, Y.; Whang-Peng, J.; Yuen, M. F.; Saif, W. M.; Tian, A.; Gu, S.; Lam, W.; Liu, S. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • FIDES-01, a phase II study of derazantinib in patients with unresectable intrahepatic cholangiocarcinoma (iCCA) and FGFR2 fusions and mutations or amplifications (M/A)
    Meeting Abstract

    Javle, M. M.; Shaib, W. L.; Braun, S.; Engelhardt, M.; Borad, M. J.; Abou-Alfa, G. K.; Boncompagni, A.; Friedmann, S.; Gahlemann, C. G.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)
    Meeting Abstract

    Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H. S.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Hong, Y. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Analysis of hematologic adverse events (HeAEs) in trifluridine/tipiracil (FTD/TPI)-treated patients (pts) with or without renal/hepatic impairment (RI/HI): Pooled safety analyses from TAGS and RECOURSE
    Meeting Abstract

    George, B.; Van Cutsem, E.; Hochster, H. S.; Mayer, R. J.; Ohtsu, A.; Falcone, A.; Yoshino, T.; Doi, T.; Ilson, D. H.; Arkenau, H. T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Meeting Abstract

    Hall, M. J.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Preliminary results from a phase I study of patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Giardina, J. D.; Merghoub, T.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study
    Meeting Abstract

    Chung, H. C.; Bang, Y. J.; Fuchs, C. S.; Qin, S.; Satoh, T.; Shitara, K.; Tabernero, J.; Van Cutsem, E.; Alsina, M.; Cao, Z. A.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Genomic correlates of extreme pathologic response following neoadjuvant chemotherapy in locally advanced gastric cancer to reveal distinct vulnerabilities
    Meeting Abstract

    Datta, J.; Walch, H. S.; Russo, A.; Chatila, W. K.; Vos, E.; Bhanot, U.; Janjigian, Y. Y.; Schultz, N.; Tang, L. H.; Strong, V. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pharmacokinetics/pharmacodynamics (PK/PD) of ivosidenib in patients with mutant IDH1 advanced cholangiocarcinoma from the phase III ClarIDHy study
    Meeting Abstract

    Fan, B.; Abou-Alfa, G. K.; Zhu, A. X.; Pandya, S. S.; Jia, H.; Yin, F.; Jiang, L.; Gliser, C.; Yang, H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save